title: 24-carat gold, 14-carat gold, or platinum standards in the treatment of critical limb ischemia: bypass surgery or endovascular intervention?
abstract: Critical limb ischemia (CLI) remains a poorly understood, rarely reported, and inconsistently treated major global healthcare epidemic. The incidence in the US is estimated at 1% of the population aged 50 years and older and at approximately double that rate in the over-70 age group. These frequencies are expected to increase significantly with the aging population and the expected increase in diabetes. Within 1 year of being diagnosed with CLI, 40% to 50% of the now 20 million US diabetics will experience an amputation, and 20% to 25% will die. The estimate for treating CLI in the US alone is $10 to $20 billion per year, but just a 25% reduction in amputations could save $2.9 to $3.0 billion annually. Infrainguinal bypass surgery (IBS) utilizing autogenous saphenous vein has been considered the "24-carat gold standard" treatment for CLI, but over the last decade, endovascular therapy has emerged to seriously challenge IBS, which has created considerable controversy. Despite an overall lack of "hard" level I data, many interventionists are questioning the role of IBS as a first-line CLI therapy or are at least now considering IBS a "tainted" gold standard ("14-carat"). This review will examine the available evidence, but there should be no doubt regarding the huge global clinical and economic impact of CLI and amputations.
authors.affiliation: Louisiana Cardiovascular and Limb Salvage Center, APMC, Lafayette, Louisiana 70506, USA. david.allie@CV-LimbSalvage.com
authors.forename: David E
authors.initials: DE
authors.lastname: Allie
authors.forename: Chris J
authors.initials: CJ
authors.lastname: Hebert
authors.forename: Agostino
authors.initials: A
authors.lastname: Ingraldi
authors.forename: Raghotham R
authors.initials: RR
authors.lastname: Patlola
authors.forename: Craig M
authors.initials: CM
authors.lastname: Walker